Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 12 | 2020 | 332 | 1.950 |
Why?
|
| Bacterial Infections | 3 | 2014 | 51 | 0.860 |
Why?
|
| Communicable Diseases | 2 | 2019 | 20 | 0.770 |
Why?
|
| Drug Utilization | 5 | 2014 | 49 | 0.730 |
Why?
|
| Anti-Infective Agents | 6 | 2016 | 44 | 0.660 |
Why?
|
| Drug Resistance, Bacterial | 4 | 2016 | 47 | 0.640 |
Why?
|
| Pneumonia, Bacterial | 2 | 2013 | 32 | 0.470 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2013 | 14 | 0.460 |
Why?
|
| Clostridium difficile | 3 | 2015 | 12 | 0.430 |
Why?
|
| Enterocolitis, Pseudomembranous | 3 | 2015 | 9 | 0.430 |
Why?
|
| Hospitals | 2 | 2014 | 109 | 0.420 |
Why?
|
| Vancomycin | 4 | 2016 | 22 | 0.410 |
Why?
|
| Encephalitis | 1 | 2013 | 4 | 0.410 |
Why?
|
| Drug Hypersensitivity | 1 | 2013 | 9 | 0.410 |
Why?
|
| Cytosine | 1 | 2013 | 10 | 0.410 |
Why?
|
| BK Virus | 1 | 2013 | 6 | 0.410 |
Why?
|
| Tumor Virus Infections | 1 | 2013 | 21 | 0.410 |
Why?
|
| Polyomavirus Infections | 1 | 2013 | 21 | 0.400 |
Why?
|
| Hospitalization | 2 | 2020 | 488 | 0.400 |
Why?
|
| Urinary Tract Infections | 1 | 2013 | 46 | 0.390 |
Why?
|
| Health Personnel | 1 | 2014 | 130 | 0.390 |
Why?
|
| Bacteremia | 1 | 2013 | 65 | 0.390 |
Why?
|
| Antiviral Agents | 1 | 2013 | 108 | 0.390 |
Why?
|
| Drug Utilization Review | 3 | 2016 | 18 | 0.360 |
Why?
|
| Tuberculosis, Hepatic | 1 | 2010 | 2 | 0.330 |
Why?
|
| Humans | 26 | 2020 | 32798 | 0.300 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 100 | 0.300 |
Why?
|
| Rocky Mountain Spotted Fever | 3 | 2008 | 8 | 0.300 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 121 | 0.300 |
Why?
|
| Rickettsia Infections | 2 | 2008 | 2 | 0.290 |
Why?
|
| Students, Medical | 2 | 2013 | 132 | 0.290 |
Why?
|
| Tick-Borne Diseases | 2 | 2006 | 2 | 0.280 |
Why?
|
| Sepsis | 2 | 2016 | 165 | 0.280 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2007 | 5 | 0.270 |
Why?
|
| Drug Therapy | 1 | 2007 | 16 | 0.270 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2007 | 12 | 0.270 |
Why?
|
| Health Expenditures | 1 | 2007 | 68 | 0.260 |
Why?
|
| Drug and Narcotic Control | 2 | 2016 | 2 | 0.250 |
Why?
|
| Metronidazole | 2 | 2015 | 18 | 0.230 |
Why?
|
| Empirical Research | 2 | 2017 | 9 | 0.230 |
Why?
|
| Rickettsia | 2 | 2008 | 3 | 0.230 |
Why?
|
| Cross Infection | 3 | 2011 | 56 | 0.230 |
Why?
|
| Gift Giving | 1 | 2005 | 2 | 0.230 |
Why?
|
| Drug Industry | 1 | 2005 | 17 | 0.220 |
Why?
|
| Curriculum | 2 | 2018 | 211 | 0.220 |
Why?
|
| Interprofessional Relations | 1 | 2005 | 43 | 0.220 |
Why?
|
| Internal Medicine | 1 | 2005 | 55 | 0.220 |
Why?
|
| Marketing | 1 | 2005 | 41 | 0.220 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2005 | 79 | 0.210 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 79 | 0.200 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 188 | 0.200 |
Why?
|
| Drug Therapy, Combination | 5 | 2017 | 289 | 0.200 |
Why?
|
| Drug Resistance, Microbial | 1 | 2002 | 14 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 3 | 2011 | 412 | 0.190 |
Why?
|
| Diarrhea | 1 | 2002 | 58 | 0.190 |
Why?
|
| Adult | 8 | 2017 | 9560 | 0.190 |
Why?
|
| Protein C | 1 | 2002 | 2 | 0.180 |
Why?
|
| Blood Coagulation | 1 | 2002 | 18 | 0.180 |
Why?
|
| Anticoagulants | 1 | 2002 | 136 | 0.170 |
Why?
|
| Female | 12 | 2020 | 20261 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 11 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2019 | 23 | 0.160 |
Why?
|
| Documentation | 1 | 2020 | 47 | 0.150 |
Why?
|
| Middle Aged | 8 | 2020 | 12125 | 0.150 |
Why?
|
| Male | 11 | 2020 | 19641 | 0.150 |
Why?
|
| Physicians | 1 | 2019 | 165 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 130 | 0.130 |
Why?
|
| Cephalosporins | 1 | 2017 | 9 | 0.130 |
Why?
|
| Penicillanic Acid | 1 | 2016 | 6 | 0.130 |
Why?
|
| Pneumonia | 1 | 2016 | 64 | 0.120 |
Why?
|
| North Carolina | 3 | 2020 | 1546 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2017 | 3438 | 0.120 |
Why?
|
| Organizational Policy | 1 | 2015 | 24 | 0.120 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 53 | 0.100 |
Why?
|
| beta-Lactams | 1 | 2013 | 7 | 0.100 |
Why?
|
| Gram-Negative Bacteria | 1 | 2013 | 8 | 0.100 |
Why?
|
| Tetracycline | 1 | 2013 | 13 | 0.100 |
Why?
|
| Fluoroquinolones | 1 | 2013 | 11 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2013 | 22 | 0.100 |
Why?
|
| Clinical Medicine | 1 | 2013 | 13 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2016 | 3701 | 0.100 |
Why?
|
| Bacteria | 1 | 2013 | 55 | 0.100 |
Why?
|
| Risk | 1 | 2013 | 315 | 0.100 |
Why?
|
| Program Evaluation | 2 | 2016 | 181 | 0.090 |
Why?
|
| Aged | 6 | 2017 | 10538 | 0.090 |
Why?
|
| Hospitals, Community | 1 | 2011 | 12 | 0.090 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 14 | 0.090 |
Why?
|
| Hospitals, Rural | 1 | 2011 | 12 | 0.090 |
Why?
|
| Infection Control | 1 | 2011 | 29 | 0.090 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 28 | 0.090 |
Why?
|
| Antitubercular Agents | 1 | 2010 | 8 | 0.080 |
Why?
|
| United States | 5 | 2016 | 4108 | 0.080 |
Why?
|
| Drug Prescriptions | 2 | 2013 | 58 | 0.080 |
Why?
|
| Formularies as Topic | 1 | 2007 | 3 | 0.070 |
Why?
|
| Tablets | 1 | 2007 | 11 | 0.070 |
Why?
|
| Prescription Fees | 1 | 2007 | 6 | 0.070 |
Why?
|
| Cost Sharing | 1 | 2007 | 10 | 0.070 |
Why?
|
| Drugs, Generic | 1 | 2007 | 15 | 0.070 |
Why?
|
| Cost Control | 1 | 2007 | 18 | 0.070 |
Why?
|
| Institutional Practice | 1 | 2006 | 1 | 0.060 |
Why?
|
| Infectious Disease Medicine | 2 | 2016 | 4 | 0.060 |
Why?
|
| Epidemiology | 2 | 2016 | 6 | 0.060 |
Why?
|
| Rickettsiaceae Infections | 1 | 2006 | 1 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 4032 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2017 | 205 | 0.060 |
Why?
|
| Persuasive Communication | 1 | 2005 | 4 | 0.060 |
Why?
|
| Training Support | 1 | 2005 | 5 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2005 | 35 | 0.060 |
Why?
|
| Social Perception | 1 | 2005 | 25 | 0.060 |
Why?
|
| Commerce | 1 | 2005 | 69 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2005 | 459 | 0.050 |
Why?
|
| Virginiamycin | 1 | 2003 | 2 | 0.050 |
Why?
|
| Oxacillin | 1 | 2003 | 5 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2003 | 54 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2002 | 45 | 0.050 |
Why?
|
| Parasitic Diseases | 1 | 2002 | 5 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2003 | 78 | 0.050 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2002 | 12 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2002 | 30 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2002 | 14 | 0.050 |
Why?
|
| Microcirculation | 1 | 2002 | 64 | 0.050 |
Why?
|
| Thrombosis | 1 | 2002 | 81 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 576 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2020 | 31 | 0.040 |
Why?
|
| Animals | 3 | 2008 | 7569 | 0.040 |
Why?
|
| Preceptorship | 1 | 2018 | 4 | 0.040 |
Why?
|
| Inflammation | 1 | 2002 | 536 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2018 | 75 | 0.040 |
Why?
|
| Prognosis | 1 | 2002 | 1544 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 53 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 947 | 0.030 |
Why?
|
| Piperacillin | 1 | 2016 | 6 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 97 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2002 | 1460 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 259 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2008 | 526 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 329 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 565 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 189 | 0.030 |
Why?
|
| Critical Illness | 1 | 2015 | 84 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 486 | 0.030 |
Why?
|
| Health Policy | 1 | 2013 | 93 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 2183 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 2327 | 0.020 |
Why?
|
| Arachnid Vectors | 1 | 2008 | 1 | 0.020 |
Why?
|
| Ixodidae | 1 | 2008 | 1 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2008 | 29 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2008 | 31 | 0.020 |
Why?
|
| Microbiological Techniques | 1 | 2006 | 1 | 0.020 |
Why?
|
| Policy Making | 1 | 2006 | 19 | 0.020 |
Why?
|
| Anaplasmosis | 1 | 2006 | 1 | 0.020 |
Why?
|
| Ticks | 1 | 2006 | 1 | 0.020 |
Why?
|
| Ehrlichiosis | 1 | 2006 | 2 | 0.020 |
Why?
|
| Doxycycline | 1 | 2006 | 26 | 0.020 |
Why?
|
| Penicillin Resistance | 1 | 2003 | 1 | 0.010 |
Why?
|